Technology Tracks Agenda

DRUG DISCOVERY CONFERENCE 18th February, 2014 PARTNERS: Dr. Reddy's Institute of LifeSciences (ILS), CSIR-Central Drug Research Institute (CDRI) Draft Agenda Key Note: 9:30 A.M - 10:15 A.M

Subject 1 : 10:15 A.M -11:15 A.M Emerging Targets: ProteinProtein Interactions (PPI) and Signaling Pathways Focus: Cancer, Neurological

Transforming to a Patient-Based Drug Discovery Approach Dr. AV RamaRao, Founder & Chairman, AVRA Labs, Hyderabad* Chair: Professor Goverdhan Mehta, Univ of Hyderabad and Dr. Prabhat Arya, DRILS, Hyderabad Chair: Dr. Prabhat Arya, DRILS Hyderabad and Dr. J.B Gupta, GVKBio Hyderabad Speakers: • Dr. Sudhir Krishna, NCBS, Bangalore • Dr. Sorab Dalal, ACTREC, Mumbai • Dr. Prasenjit Mitra, DRILS Hyderabad

Disorders & Metabolic Disorders

11:15 A.M -11:30 A.M Subject 2 : 11:30 A.M -12:30 P.M Functional Assays and Highthroughput Screens Subject 3 : 12:30 P.M - 01:30 P.M 3D Cell Biology for Screening

01:30 P.M -02: 45 P.M 02:45 P.M -03:15 P.M

Subject 4 : 03:15 P.M -04:15 P.M Chemical vs Biological Space Round Table : 4:15 P.M - 05-00 P.M Problem Solving Agenda (Round Table)

TEA BREAK Chair: Dr. Kiranam Chatti and Dr. Prasenjit Mitra, DRILS Hyderabad Speakers: • Dr. Monalisa Chatterji, Astra Zeneca, Bangalore • Dr. Kiranam Chatti, DRILS Hyderabad • Dr. Prasenjit Mitra, DRILS Hyderabad Chair: Dr. Gael Stephant, Paris* or Dr. Mike Renard* • 3D Microtissues and Cell based Assays • Toxicology Screens Speakers: • Dr. Wolfgang Moritz*/ Dr. Jens Kelm Insphero, Switzerland* • Dr. Keith Murphy, Organovo, US* LUNCH BREAK Innovation Talks: A Novel Versatile Human Cell Based in Vitro High Throughput Genotoxicity Screen Dr. Sunilkumar Sukumaran, Anthem Bioscience Bangalore Chair: Dr. Prabhat Arya and Dr. Amit Mandal, DRILS Hyderabad Speakers: • Dr. G. Narahari Shastry, IICT Hyderabad • Dr. Prabhat Arya, DRILS Hyderabad Strength of small molecules pipeline – Drivers & Barriers Moderator - Dr. Prabhat Arya, DRILS Hyderabad and Mr. Arvindh Shanmugam, Independent Consultant, Chennai • Enzyme vs protein-protein interaction-based targets • Functional assays • Chemical vs biological space • Upcoming challenges and opportunities for the CROs • Basic science discovery to translational path • Fostering academia-industry relationship to develop new research models Panel: Dr. JB Gupta - GVKBIO, Dr. Nishi - CEO Daiichi, Dr. CSN Murthy, Aurigene,Dr. Reddy's, Jubilant, Dr. Raman Bakshi -Syngene, Dr. Satish Jindal - BMS, ChemBioTech, Dr. Renu Swarup, DBT - BIRAC

BIO-THERAPEUTICS CONFERENCE 18th February, 2014 Organizers: Federation of Asian Biotech Association, Government of Andhra Pradesh, Pharmexcil, Ministry of Commerce & Industry, Government of India Partners: Insight Bioventures India Private Limited, ACTREC, United States Pharmacopeia

Draft Program Agenda 9:30 - 10:15 Hrs Keynote

10:15 -11:15 Hrs (Subject 1) Next Generation Biologics

11:15 -11:30 Hrs 11:30 A.M -12:30 P.M (Subject 2) Cancer BioTherapeutics

12:30-13:45 Hrs 13:45-15:30 Hrs (Session 3) Coordinated by United States Pharmacopeia

15:30-16:15 Hrs (Session 4) Bio-Engineering & Bioprocessing Innovation

16:15- 17.00Hrs

Bio-Therapeutics - Unfolding Next Generation Biologics Prevention of infections linked to human cancers Prof. Dr. Harald zur Hausen (Nobel Laureate), University of Heidelberg, Germany mRNA CAR Engineered T-cell Immunotherapies Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington Therapeutic Proteins for Diabetic foot ulcer (DFU) Dr. Theresa O'Keefe, Mend Therapeutics Inc., Boston Multispecifics: DVD-iG Technology Dr. Subramanya Hegde *, AbbVie Inc., Boston Tea / Coffee Break Chair: Dr. Shubhada Chiplunkar* , Director, ACTREC Development & Commercialization of Enhanced Potency Dendritic Cell Vaccines for Cancer Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington Lethal Seeds in the Womb: Endometrial Cancer Stem Cells Express Metastasis Tumor Antigen Dr. Asha Nair, Rajiv Gandhi Centre for Biotechnology, Kerala Lunch Break Critical Quality Attributes of Biotherapeutic Proteins and Biosimilars Dr. Sridevi Khambhampaty, Sr. Director, Dr. Reddy’s lab Critical Quality Attributes of Vaccines Dr. Mahesh Bhalgat, COO, Shantha Biotech Quality Attributes of Biologic Medicines and USP Standards Dr. Ranjan Chakrabarti, Vice President, United States Pharmacopeia-India Dr. Ralf Klein ViruSure GmbH Alternative expression system that will reduce the cost of production of therapeutic proteins Dr. Jagmohan Singh, IMTECH Rapid scalable. cGMP-compliant 'plug and play' platform for Manufacture of Multigram Quantities of Recombinant Proteins, Antibodies & Vaccines Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington Problem Solving Framework - Next Generation Biologics in India – Drivers & Resistors

* indicates invited confirmation awaited

BIO-ENERGY CONFERENCE 18th February, 2014 PARTNERS: Ministry of New and Renewable Energy (MNRE), The Energy and Resources Institute (TERI), & CSIR-Indian Institute of Chemical Technology (CSIR-IICT) Draft Agenda 09:00-09:30 A.M

INAUGURATION by Dr Satish Balram Agnihotri, Secretary to Government of India, Ministry of New and Renewable Energy* Sustainability Assessment to Promote Holistic Bio-Energy Production – Feedstock, Technology & Regulations

9:30 - 10:15 A.M Keynote

Dr. Jean-Marc Jossart *, Secretary General, AEBIOM-European Biomass Association, Belgium (or) Dr. David Hurlbut *, National Renewable Energy Laboratory, USA Chair: Mr. Amit Kumar *, Director, Energy-Environment Technology Development Division, TERI, New Delhi - Energy Plants – Alternatives -Agri-residue biomass collection, logistics -Algae -Biomass -Next Generation Alternatives

10:15 - 11:15 A.M (Session 1) Bio-Feedstock Supplies– Proposed Speakers comparative analysis • Dr. Murali Sastry, Director, DSM India Innovation Centre of various feedstock • Dr Pankaj Patel - Director, Abellon CleanEnergy Ltd sources • Dr.Ashwani Kumar, BioEnergia • Dr. Shibu Jose, UM, Columbia, MO, USA • Dr. D K Tuli , Executive Director & Centre Coordinator, DBT-IOC Advanced BioEnergy Research Centre, Indian Oil Corporation Ltd, Faridabad • Dr Ahmed Kamal, IICT, Hyderabad • Dr P Srinivasa Rao, Senior Scientist, ICRISAT, Patancheru, India • Dr. Priyangashu Sarma , Fellow, TERI, New Delhi 11:15 -11:30 A.M Tea / Coffee Break Chair – Mr. A P Dhussa *, Scientist-G/Advisor, Ministry for New and Renewable Energy, Government of India, New Delhi /Dr Ahmed Kamal *, Outstanding Scientist, CSIR-IICT, Hyderabad and Director, NIPER, Hyderabad 11:30-12:30 P.M (Session 2) -Bio-Refinery Technologies BEMA: -Genetic Improvement of Energy Crops Biotechnology, -Strains and Enzyme Technology (Biomass Digestion) Engineering, Micro- -Mass Production of Energy Crops Biology & Agriculture Proposed Speakers • Prof. K T Shanmugam, University of Florida, USA • Prof. Hornung, Director - European Bioenergy Research Institute • Dr. Arvind Lali, Centre Coordinator, DBT-ICT Center for Energy Biosciences, Institute of Chemical Technology, Mumbai

• • • • • •

Mr. Laxmi Narasimhan, General Manager, Centre for Novel Catalytic Materials, Shell Technology Centre, Shell India Marketing, Bangalore Dr S V Ramakrishna (earlier worked with Reliance and Praj in their biofuel programs as research director) Mr. Subramani Ramachandrappa - CMD Richcore India DrAlok Adholeya, Director, Biotechnology and Management of Bio-resources Division, TERI, New Delhi Dr. Ashok Pandey, Head, Centre for Biofuels, NIIST, Thiruvananthapuram (If a speaker needed on liquid fuels) Dr. Piyali Das, Fellow, TERI, New Delhi

Chair - Mr. Pramod Chaudhari *, Executive Chairman, Praj Industries Limited and Chairman, Praj Group, Pune, India

12:30-1:30 P.M (Session 3) Industrial Bio-energy & Commercial Deployment

1:30 - 2:45 P.M 2:45 - 3:15 P.M

-Torreication Technology -CHP Deployment & scalability -DFC for Anaerobic Digestion -Industrial bio-energy economics Proposed Speakers • Dr. Ludo Diels, Senior Scientist and Head of the Environmental and Process Technology Centre, VITO, Belgium • Dr Syed Isa Syed Alwi, CEO, AlgaeTech International, Malaysia • Dr. R R Sonde, Executive Vice President, Research, Technology & Innovation, Thermax India • Mr. Sunil Dhingra, Senior Fellow, TERI, New Delhi • Dr. Balu Sarma Lunch Break Innovation Talk K.Sudhakar, NIT-Bhopal & Five more speakers Chair - Shri Alok Srivastava *, Joint Secretary, Ministry for New and Renewable Energy, Government of India, New Delhi

3:15 - 4:15 P.M (Session 4) Regulations – New & Renewable Energy as a legislation & Directive

4:15 - 5:30 P.M

Proposed Speakers • Dr. Chris Mottershead, The Carbon Trust, London, UK / Richard Adams, NREL / David Hurlburt NREL Policy Analysis group • Dr. Renu Swarup, Adviser, Department of Biotechnology, Ministry of Science & Technology, Government of India and Managing Director, Biotechnology Industry Research Assistance Council • Mr. Anil Kumar Jain, Adviser (Energy), Planning Commission, Government of India • Dr K V Raghavan, Vice President, FABA, Ex Director CSIR-IICT, Hyderabad • Mr. K Krishan, Chairman CII Task force on Bioenergy and Chairman, MPPL Renewable Energy Pvt. Ltd. • Prof. Janaki/Dr Pankaj USA Problem Solving Agenda Creating the Bio-Energy Economy of India – Drivers & resistors

Coordinated by PHARMEXCIL

GENOMIC-PERSONALIZED MEDICINE CONFERENCE Hyderabad International Convention Center, Hyderabad Chairman: Prof. Donald W. Weaver, Surgeon-in-Chief, Detroit Medical Center (DMC), Chief of Surgery at Harper University Hospital, Chairman of Department of Surgery, Wayne State University School of Medicine, USA Conveners: 

Dr. Ramesh B. Batchu, Associate Professor, Dept Surgery, School of Medicine Director, Division of Surgical Oncology & Developmental Therapeutics, Dept Immunology and Microbiology, John D Dingell VAMC, Wayne State University



Dr Cirino Botta, MD, Medical Oncology Unit, Fondazione Tommaso Campanella & Magna Graecia University of Catanzaro, Italy

Draft Program Agenda 09:30-10:00 Hrs

“Personalized Medicine: Tailor-made for individual patient” Personalized medicine is the ability to determine an individual's unique molecular characteristics to propose customization of medical care more finely suited to a patient.

The availability of genetic information due to successful human genome project has played a major role in the ability to predict an individual's susceptibility to diseases.

This will allow protocols designed specifically based on the patient’s response to treatment.

Prof. Donald W. Weaver MD, FACS, Surgeon-in-Chief, Detroit Medical Center (DMC), Chief of Surgery at Harper University Hospital, Chairman of Department of Surgery, Wayne State University School of Medicine, USA

10:00-10:20 Hrs

Adeno-associated Viral vectors in Genomic Medicine and cell based treatment Gene therapy with traditional viral vectors is limited by a variety of practical and theoretical concerns, such as the immunogenicity of viral capsid proteins and insertional mutagenesis. Adeno-associated virus (AAV) is a small, 4.7kb, non-enveloped DNA virus initially identified as a contaminant in adenoviral preparations. Bioengineered recombinant AAV (rAAV) vectors are preferred for gene therapy due to their lack of pathogenicity, wide range of infectivity, and ability to establish long-term transgene expression in non-dividing cells. Furthermore, with only a modest frequency of integration into the host genome, they avoid insertional mutagenesis. Finally, rAAV vectors per se induce only weak innate immune responses when compared to other

For registrations Contact – info@bioasia.in | Telephone: +91-40-6644-6477/6577

Coordinated by PHARMEXCIL viral-based vectors. rAAV vectors have yielded promising results in an increasing number of somatic gene therapy clinical trials without any significant adverse events.

However, despite the well-established safety of rAAV vectors for in vivo gene transfer, several challenges remain, such as achieving high levels of transduction in targeted organs and inhibiting cytoplasmic degradation of a high percentage of virions during intracellular trafficking to the nucleus. Indeed, rAAV capsids are phosphorylated, marking them for ubiquitination followed by proteasome-mediated degradation in the cytosol. Thus, higher doses of vectors are needed to obtain therapeutically relevant concentrations in patients. The development of next generation of capsid-modified rAAV vectors, which bypass ubiquitination and proteasome degradation, leading to high efficiency gene transfer and transgene expression at reduced doses, and their utility in genomic medicine will be discussed.

Dr. Arun Srivastava, George H. Kitzman Professor of Genetics and Chief of Division of Cellular & Molecular Therapy in the Departments of Pediatrics, and Molecular Genetics & Microbiology, and Powell Gene Therapy Center, University of Florida, USA 10:20-10:40 Hrs

Urological cancers, biomarkers and cancer pathway inhibitors Immune status of every tumor and the way its cells respond to the local environment is different, based on the genetic profile of patients. The tumor grade may be the same from patient to patient, but the pathways for escape and resistance may be different.

Genomics and proteomics-guided treatment of individual patients is the direction we should be taking to manage malignancies. This holds true not only when it comes to predicting progression and aggression of tumors where we need to be pairing therapeutics based on the genetic/protein marker. Each patient with urological cancer has a distinct histology, a different clinical course and responds differently to therapy.

For example genomic studies in identifying the genes for kidney cancer, such as fumarate hydratase, and succinate dehydrogenase have significantly altered the ways in which patients with kidney cancer are managed.

Dr. Jose Pontes, MD, Urologist, Detroit, MI, USA

10:40-11:00 Hrs

Tea / Coffee Break

11:00-11:20 Hrs

Gene-based treatment for Head and Neck Cancers Although some head and neck cancers are diagnosed early in the disease progression, silent lesions unfortunately are not diagnosed until regional spread has already occurred. The stage at the time of diagnosis for cancer of larynx with early symptoms of hoarseness is much lower than that of a base of tongue cancer, which often lacks symptoms, until later in the disease course. Infection with human papilloma virus (HPV) increases one’s odds of developing squamous cell carcinoma of the oral pharynx.

As smoking has decreased, the incidence of HPV associated cancers has increased.

Understanding the genetic basis of this specific subtype of cancer could allow therapeutic targeting of affected pathways for a stratified medicine approach. Gene profile analysis of various head and neck cancers revealed altered pathways in p53 and

For registrations Contact – info@bioasia.in | Telephone: +91-40-6644-6477/6577

Coordinated by PHARMEXCIL Rb mutation and copy number alteration of PI3 kinase pathway. Additional observations of alternative pathways have been made in cancers of the thyroid. Whole genome sequencing and identification of gene expression patterns will be required to gain a complete understanding of the genetic basis of head and neck cancers to provide the foundation for the development of effective forms of therapy.

Prof. John R Jacobs MD FACS, Departments Otolaryngology Head and Neck Surgery, Wayne State University, Karmanos Cancer Center, USA 11:20-11:40 Hrs

Genetic Immunotherapy with Dendritic Cells for Individualized Cancer Vaccine Dendritic cells (DC) are highly specialized antigen-presenting immune cells and key regulators of the immune responses that orchestrate innate and adoptive immunities throughout the body. They are responsible for identifying tumor markers to activate cytotoxic T lymphocytes, which then multiply and attack only the diseased cells, but not normal healthy cells. This is a potent form of immunotherapy to harness the body's own immune system to fight cancer. Use of non-pathogenic recombinant adeno-associated viral (rAAV) vectors can achieve high levels of intracellular tumor specific gene expression in DCs with much lower doses of vector and generation of robust cellular anti-tumor immune responses. Gene-vector based immunotherapy with DCs would pave the way for development of a therapeutic vaccine strategy to achieve durable tumor regression specific to individual patients.

Prof. Selvarangan Ponnazhagan, Endowed Professor in Experimental Cancer Therapeutics, The University of Alabama at Birmingham, USA

11:40-12:00 Hrs

Personalized Therapeutic Vaccines Therapeutic vaccinology will allow the development of personalized vaccines based on our increasing understanding of immune response phenotype: genotype information.

Rapid advances in developing such data are already occurring for numerous diseases and newly available data suggest that some vaccine-related adverse events may also be preventable based on genetic prediction.

Dr. Bala Krishna Kolli, Rosalinda Franklin University of Medicine and Science, North Chicago, IL, USA

12:00-12:20 Hrs

Role of Bioinformatics in Personalized Medicine In the genomic era: doctors and patients will have access to genetic data to customize medical treatment. In recent past, molecular science has made many advances to benefit medicine, including the Human Genome project, International HapMap project and genome wide association studies (GWASs) (International HapMap Consortium, 2005).

Single nucleotide polymorphisms (SNPs) are now recognized as the main cause of human genetic variability and are already a valuable resource for mapping complex genetic traits. Thousands of DNA variants have been identified that are associated with diseases and traits. By combining these genetic associations with phenotypes and drug response, personalized medicine will tailor treatments to the patients’ specific genotype.

For registrations Contact – info@bioasia.in | Telephone: +91-40-6644-6477/6577

Coordinated by PHARMEXCIL Anticancer drugs which target to specific cancers, and use of pharmacogenetic dosing algorithm, reduction of incidence of adverse events by screening for susceptible genotypes for certain drugs underscore the importance of bioinformatics approach in personalized medicine.

Dr. Ravindra B Potti, Associate Professor, Department of Biotechnology, Sreenidhi Institute of Science and Technology, Hyderabad 12:20-13:00 Hrs

Interaction and Close

For registrations Contact – info@bioasia.in | Telephone: +91-40-6644-6477/6577

Bio-IT Conference 19th February, 2014 Draft Agenda Key Note: 9:30 A.M - 10:15 A.M Subject 1 : 10:15 A.M - 11:15 A.M Computational Therapeutics

BioPharma Big Data Paradigm Dr. Nitish Chawla, University of Notre Dame, Indiana, US (2013 IBM Big Data Innovation Award winner) Session Chair: Dr. Vellarkad N. Viswanadhan, Jubilant Biosys Computational Drug Design Dr. Frank Hollinger - Sphaera Pharma Computation Guided Vaccine Design Integrative approach for designing of Epitope-based vaccine using in silico platform OSDD Linux Dr. GPS. Raghava – IMTECH

11:15 A.M - 11:30 A.M Subject 2 : 11:30 A.M - 12:30 P.M Cross Platform Omics for Translation Research

Blast Off! Exploring the universe of biochemical reactions Dr. Rahman Syed Asad., EMBL – EBI, Cambridge, UK TEA BREAK BioMarker Discovery for Translational Prediction Dr. Pramila Tata - Strand Life Sciences Integrative Omics – Interactome Models Mr. Jignesh Bhate – Molecular Connections Translational Informatics Dr. Ajay Shah, City of Hope, CA, US*

Subject 3 : 12:30 P.M - 1:30 P.M Data capture & Analytics

Systems Pharmacology Dr. Rajgopal Srinivasan – TCS Innovation Labs Chair: Mr. Raghu Rangaswamy, Schroedinger Preserve, Protect & Collaborate via Scilligence Informatics (ELN) Mr. Rajiv Hotchandani- Scilligence Data Pipeline Management: Pipeline Pilot Proposed: Accelrys Registration Systems (Chemical & Biological) Mr. Ivan Solt – Chemaxon, Hungary*

1: 30 P.M - 02:30 P.M

Process Analytics: Reaction Data Kit Demonstration Mr. Ramakrishna Bodi, KNIME* Lunch Break

02:30 P.M - 03:00 P.M

Innovation Talks

Subject 4 : 03:00 P.M - 04:00 P.M Big Omics Data Management, Challenges

Drug R & D Knowledge Mining Made Simple: A Scilligence Perspective Dr. Jinbo Lee, CSO, Scilligence Cloud Computing and Innovations for Optimizing Life Sciences Research Ms. Krittika Sasmal , iOMICS, InterpretOmics SaaS, IaaS and PaaS options for IT Investment Optimization Proposed Speaker from Accenture, IBM

Round Table : 4:00 P.M - 04-30 P.M Problem Solving Agenda

Problem Solving Agenda: Bio-IT – Leveraging IT Investments in Bio-Pharma R&D (Drivers & Barriers)

REGENERATIVE MEDICINE CONFERENCE 19th February, 2014 PARTNERS: Integrative Regenerative Medicine (IGEN) Center, Society for Tissue Engineering & Regenerative Medicine (STERMI), Sankara Netralaya Translational Research Institute (SNTRI) Draft Agenda Key Note: 9:30 A.M - 10:15 A.M

Subject 1 : 10:15 A.M -11:15 A.M Comparative Therapeutic Potential of various Stem Cell

Chair: Prof. Zee Upton, Queensland University of Technology Guest: Dr. Michael West, Chairman BioTime Inc. Doing more with less: Frugal innovation in Regenerative Medicine – Dr. Mahendra Rao, Director The NIH Center for Regenerative Medicine, USA Chair: Dr. Utpal Banerjee, UCLA* Embryonic Source (Pure Stem) Dr. Jeffey Janus, ESI Bio/BioTime (or) Dr. James Kehler, BioTime Induced Pluripotent Stem Cells – Dr. Ullas Mony* Dr. Alok Srivastava, CMC* Dr. James Byrne, UCLA* Adult stem cells, their potential and their comparison with ESCs Dr. Chandra Viswanath - Reliance Life Sciences

11: 15 A.M–11: 30 P.M Subject 2 : 11:30 A.M -12:30 P.M Characterization, Reprogramming, Differentiation & Analysis of Stem Cells

Therapeutic potential of Hematopoietic and Mesenchymal stem cells derived from cord tissues Dr. Lalitha Limaye, NCCS, Pune TEA BREAK Chair: Dr. Vincent Zurawski, Hepregen Corporation* Biomarker discovery for stem cells using omics, Dr. Vivek Tanavde, Bioinformatics Institute, Singapore Cell Reprogramming Dr. P Chandrashekar, inStem* Epigenetic analysis & Characterization Dr. Rachna Goyal, Lonza

Subject 3 : 12:30 P.M -01:30 P.M 3D Biology & Tissue Engineering

Engineering Adult Stem Cells to Enhance their Potency & Therapeutic Efficacy Dr. Madhusudan Peshwa, MaxCyte, Inc. Washington Chair: Dr. Seeram Ramakrishna - NUS, Center for Nanofibres & Nanotechnology Biomimetic Building Blocks Dr. Jaywant Phophase, IGEN, Linkoping University, Sweden 3D Biology for RM Dr. Gael Stephant, Paris* Tissue Engineering & Bio-printing Technology Dr. Sourabh Ghosh, IIT Delhi Bio-printing Technology Dr. Keith Murphy, Organovo, San Diego* Dr. Michael Renard, Organovo, San Diego* Brain Organoids Dr. Juergen Knoblich, IMBA - Institute of Molecular Biotechnology, Austria* (Or) Liver Organoids Dr. Nuria Montserrat, Centre of Regenerative Medicine in Barcelona*

1:30 P.M -2:30 P.M

LUNCH BREAK

02:30 P.M -03:00 P.M

Innovation Talks

Subject 4 : 3:00 P.M -04:00 P.M Specialty Trends

Chair: Prof. Nisha R Agrawal, Banaras Hindu University, Varanasi Bone & Cartilage Dr. Sudhir Kumar Reddy, ISCO Cell Therapeutics Neural Dr. NK Venkatarama*/Dr. Basha Paspala Cardiac Dr. Arjun Deb, MD, Board of Stem Cells, UCLA, USA*

Round Table : 4:00 P.M – 04:30 P.M

Ophthalmology Dr. Krishna Kumar, Vision Research Foundation, Sankara Nethralaya Dr. Doris Taylor, Centre for Cardiovascular, University of Minnesota* Problem Solving Agenda : Stem Cell & Regenerative medicine - Drivers & Barriers

Medical Electronics and Devices Conference 19th February, 2014

DRAFT AGENDA 09:30 – 10:15 Hrs

INAUGURAL CEREMONY Chief Guest: Minister of State, Department of Commerce, Government of India* Guests of Honour: • Shri J. Satyanarayana, IAS, Secretary to the Government of India, Department of Electronics and Information Technology (DEITY), Ministry of Communications & Information Technology (Government of India)* • Shri. Pradeep Chandra IAS, Principal Secretary to the Government of Andhra Pradesh, Department of Industries and Commerce Keynote Address: India’s vision and Strategy on MedTech Dr. Ajay Kumar IAS, Joint Secretary to the Government of India, Dept. of Electronics and Information Technology*

10:15 – 11:15 Hrs

Medical Technologies – India for India “The Indian Medical Device & Equipment market is currently valued at $ 4.4 billion and is expected to grow to around $ 5.8 billion by 2014 and $ 7.8 billion by 2016, growing at a CAGR of 15.5 per cent", according to an industry report. As the sector gains traction continually over the years, there is a perpetual demand for high quality products. There were around 356 registered manufacturing units producing medical devices of the value of outputs of `312 crores in 2009‐10. There are only few units manufacturing medical devices compared to the growing manufacturing sector in India.

The session will focus on the gap between the supply and demand such that the Indian production can cater to the local demand than relying on exports Lead Speaker: Mr. M.R. Srinivas Prasad, CEO , Philips Innovation Campus Panelists: • Mr. M.R. Srinivas Prasad, CEO , Philips Innovation Campus • Mr. Suresh Sharma, Chairman & Managing Director, Allengers Medical Systems Limited* • Mr. Ajit G Nambiar, Chairman & Managing Director, BPL Healthcare* • Dr. K. K. Kalra, CEO, National Accreditation Board for Hospitals & Healthcare Providers (NABH) • Shri. Arun Sachdeva, Senior Director (Scientist‐G), Department of Electronics and Information Technology (DEITY), Government of India Moderator: Mr. Mahadevan Narayanamoni, Partner, Corporate Finance and Life Sciences, Grant Thornton

11:15 – 11:30 Hrs 11:30 – 11:45 Hrs 11:45 – 12:30 Hrs

TEA / COFFEE BREAK Opportunities in Gangwon (South Korea) MedTech – Ensuring Quality and Patient Safety Growing demand of efficacious and quality treatments has accelerated the growth of MedTech Sector. As with every new emerging technology, there are potential risks with such new technologies, and testing & calibration holds the key. Availability of skilled manpower and huge talent pool of engineers in India makes it a strategic destination for testing and calibration forglobal companies. The session shall focus on ways and means to enhance patient safety and quality of medical technologies through strengthening the testing and calibration laboratories in

India and the potential role that Industry and Government (both state and central) have to play Chairman: Mr. S. Kishore Kumar, Scientist‐F & Head, Medical and Hospital Planning, Bureau of Indian Standards, Government of India Panelists: • Mr. Sundeep Rao, Vice President, Philips Electronics India Limited* • Mr. Suresh Sugavanam. Vice President & Managing Director at Underwriters Laboratories • Mr. G. Kalyan Varma, Country Head, Products Business Stream, TUV Rheinland India • Dr. G.S.K. Velu, Managing Director, Trivitron Laboratories* • Dr. Chander Shekhar, Scientist ‐ 'F', Indian Council of Medical Research (ICMR) • Dr. Devasis Guha, Head, R & D, HLL Lifecare Limited* Moderator: Dr. Girdhar J Gyani, Director General, Association of Healthcare Providers (India)* 12:30 – 13:30 Hrs

India as Manufacturing Hub The influx of Medical Electronics technology has reinforced the existing Healthcare infrastructure in various ways right from digitizing medical test, diagnostic and therapeutic procedures to enhancing the reach of Healthcare through telemedicine and Health IT. A number of international companies have set up manufacturing facilities in India and given the tremendous benefits of cost economics, India promises to be the manufacturing hub for MedTech Lead Speaker: Mr. Vikram Damodaran, Chief Technical Officer, GE Healthcare India* Panelists: • Mr. Kaustubh Patil, Program Manager, Medtronic India Development Center* • Mr. Subramanian, Director, SCS systems* • Mr. Vinayak Khandeparker, Quality Head, Siemens India* • Dr. Shahid Jameel, Senior Scientist and Group Leader, ICGEB* Moderator: Mr. Vijay Simha, CEO, One Breadth Inc.

13:30 – 14:30 Hrs 14:30-15:30 Hrs

LUNCH BREAK Creating a conducive Policy Environment in India: Way Forward While the sector faces challenges in particularly in terms of low penetration, high capital requirement, complex rules & guidelines, acceptability, awareness, etc., the future looks extremely promising with the increased public spending & private investment in healthcare, health insurance schemes, public private partnership (ppp) route to innovation, etc. This panel is structured to be a discussion with the key policy makers to understand from them on enabling a fostering environment for the growth of the sector Panelists: • Dr. Ajay Kumar IAS, Joint Secretary to Government of India, Department of Electronics and Information Technology (DEITY)* • Mr. S. Kishore Kumar, Scientist‐F & Head, Medical and Hospital Planning, Bureau of Indian Standards, Government of India • Shri S. B. S. Reddy, ITS, Regional Jt. DGFT (Directorate General of Foreign Trade) • Mrs. Anuradha Gupta, Joint Secretary, Ministry of Health & Family Welfare (PNDT)* • Dr. Sadhana Srivastava, Scientist E, IPR Unit, Department of Health Research, Indian Council of Medical Research (ICMR) • Dr. Rashid Hasan, Director, Ministry of Environment & Forests (MoEF)* Moderator: Mr. Karan Singh, Partner, Bain & Company*

15:30-15:45 Hrs 15:45 -16:30 Hrs

China Medical City-Opportunities in China Concluding Remarks by the coordinators and Event Close Mr. Sudhakar Mairpadi, Head Regulatory Affairs, Philips Mr. Vibhav Garg, Head, Health Economics & Government Affairs, Boston Scientific